Skip to content

BetaGlue published an article on the performance and safety of BAT-90 on ‘In Vivo’

In Vivo

According to the article featured in the international peer-reviewed journal, BAT-90 could be considered a safe and innovative therapeutic option for unresectable solid liver tumors

BetaGlue Technology’s Antonino Amato and Pier Luigi Carriero, together with Gordon McVie (King’s College London), Giovanni Paganelli (Istituto Romagnolo Studio Tumori, IRCCS), Roberto Cianni and Giuseppe Maria Ettore (San Camillo/Forlanini Hospital) published the ‘In-vivo Models for the Performance and Safety of BAT-90, a Novel 90-Yttrium-based Internal Radiotherapy Platform‘ article on the September-October issue of In-Vivo, an international peer-reviewed journal on experimental and clinical biomedical research (click here to read the full article).

BetaGlue’s BAT-90 is an innovative, active implantable device designed for the irradiation of unresectable tumors (e.g., liver cancer) or of surgical tumor beds, based on the combination of Yttrium-90 beta-emitting microspheres and a biocompatible adhesive hydrogel. The rationale behind BAT-90 is to localize the Yttrium-90 radioactivity on the administration site, thanks to the adhesive hydrogel, while also minimizing its body dispersion. The effective induction of necrosis in the target injection area was shown in a pig liver model, whereas the safety of BAT-90 was demonstrated in biocompatibility tests for acute and chronic toxicity, both locally and systemically.

The study shows that BAT-90 administration induced necrosis into the target site, while the safety experiments in the treated animals highlighted results very similar to the controls. Therefore, BAT-90 could be considered as a safe and innovative treatment option for inoperable solid tumors of the liver.

Antonino Amato is the CEO and CMO of BetaGlue, while Pier Luigi Carriero is the company’s VP – Clinical Operations. Giovanni Paganelli, Roberto Cianni and Giuseppe Maria Ettore are part of Company’s Scientific Advisory Board.

In-Vivo is an international peer-reviewed journal designed to bring together original high-quality studies and reviews on experimental and clinical biomedical research within the frames